SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062417
Filing Date
2023-11-13
Accepted
2023-11-13 07:00:11
Documents
15
Period of Report
2023-11-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20231109.htm   iXBRL 8-K 73371
2 EX-4.1 ubx-ex4_1.htm EX-4.1 180568
3 EX-10.1 ubx-ex10_1.htm EX-10.1 106025
4 EX-99.1 ubx-ex99_1.htm EX-99.1 14212
  Complete submission text file 0000950170-23-062417.txt   545936

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ubx-20231109.xsd EX-101.SCH 2484
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ubx-20231109_lab.xml EX-101.LAB 13350
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ubx-20231109_pre.xml EX-101.PRE 9851
9 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20231109_htm.xml XML 4715
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

IRS No.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 231394993
SIC: 2834 Pharmaceutical Preparations